FUND  I

Influencing innovation in healthcare with strength in numbers

HIP Fund I is backed by our investing principle of a collaborative diligence process

$5M

Target Fund Size

$2M

Current Capital Raised

2

Closes Completed

$1M

Capital Deployed

5

Investments Made

30

LP’s

6

Deals In Later Stage Diligence

2

Upcoming Follow-On Investments

Along with 3 HIP VC Members

Along with 2 HIP VC Members


Along with 2 HIP VC Members

Along with 3 HIP VC Members

Along with 1 HIP VC Members

Our Investment Thesis

| Supporting the Right Unmet Needs + Fuel Growth |


The HIP Fund I is strategic capital from experienced healthcare-only LPs focused on supporting technology-based solutions that positively impact healthcare

Health Technology

Data and AI solutions centered around better decision-making and efficiency

Consumer Health

Providing consumers affordable options while improving access and healthcare spend

Health IT

Opportunistic solutions helping reduce the cost of delivering care across healthcare institutions

Digital Health

Modernizing traditional manual aspects of accessing care and related services

Life Sciences

Hardware and software across precision medicine, diagnostics and medical devices focusing on reducing cost of care and improving efficiency and outcomes

CRITERIA

  • Life Sciences: for regulatory compliance required solutions – investment window is no earlier than 12-18 months pre-FDA submission (i.e. medical devices, diagnostics and screening).
  • Health Technology, Digital Health and Health IT: requirement for MVP to be validated through pilots, or early-revenue traction. Opportunities requires a revenue plan that is established with a line of execution for18 months forward identified.
  • Consumer Health: requirement for MVP to be clinically and user-experience validated by early traction and market influencers. GTM needs to have initial testing and verification.

WHAT WE DON’T INVEST IN

  • Drug discovery or development
  • Creation of biologics or therapeutics
  • Biotechnology

What Makes Us Unique

| Control Risk + Focus on Creating Value and Returns |

01

STRATEGY

Diversified multidisciplinary collaborative ecosystem that mitigates risk and commercializes effective healthcare innovations

⎻ Collaborative ecosystem of 200+ investors
⎻ Sourcing of opportunities – 80% of pipeline comes from HIP investor network – pre-vetted deal flow
⎻ Multidisciplinary expert-led diligence – every voice counted

02

MODEL

Multi-angle deployment with value-add impact built-in

⎻ Unique LP-friendly fund structure (0% management fees)
⎻ Opportunity to participate in sidecar SPVs
⎻ Attaining investor rights and pro-rata in each investment as an early-stage investor
⎻ Syndicate opportunity with value -add VCs and Strategic Investors

03

DECISION MAKING

Early-stage investing with the most complete risk mitigation process

⎻ Multifaceted validation covering every angle (i.e. clinical, product/technology, commercialization, people/leadership)
⎻ Proprietary investing platform providing transparency on diligence and decision making to all investors
⎻ Shared decision-making based on evidence-based construct

04

EXECUTION

Smart capital deployment thesis ensuring early risk detection, growth, and returns

⎻ Required post-investment advisory model enforces return on investment thesis
⎻ Manage and guide future capital raises for startups based on a hands-on approach
⎻ Large strategic network utilized to drive commercialization and grow revenue and profitability
⎻ Provide investors an opportunity to participate in advisor roles in deals (i.e. clinical, product development, BD)

Deal Flow

| From Opportunity to Investment |


In addition to providing relevant expertise through the diligence process, HIP investors also offer invaluable advisory support post-investment to assist company growth and scale

600

Annual Deals in Pipeline

80

Annual Deals from Accelerators

70/20/10

Ratio of Seed or Seed Extension / Series A / Series B

50/50

Ratio of Follow-on Investments in Existing Portfolio / New Deals

4 Months

Average Time Spent in Diligence Before Investment

Stage and Check Size

Stage: Seed through Series A. Future plans for reserve funds for follow on. Post-investment agreement executed with value-add investors established as advisors for portfolio company.
Initial Check size: $150K-$250K
Traction: MVP with some assemble of adoption (i.e. users, revenue, date), medical device: no earlier than 12-18 months pre FDA approval.

Deal Sourcing

| Add sub-heading |


Robust healthcare-only HIP Investor Network has over 80 institutional investors including 16 US health systems – yielding over 60% of our pipeline

PARTNERSHIPS THAT SPAN THE INDUSTRY

Relationships with the largest and most reputable accelerators, incubators and professional healthcare organizations globally. Here's a small sampling: 

HEALTHCARE KOL’S AND SME’S WITH 1800+ YEARS OF EXPERIENCE

The HIP Investor Network also includes over 120 non-institutional investors who are healthcare industry executives, entrepreneurs and clinicians. Their active support results in over 25% of our pipeline. Here's a small sampling: 

HIP Institutional Investors and Co-Investors

Focused and purposeful collaborative ecosystem gives us an unmatched ability to not only co-invest but also leverage our partners in diligence and decision-making.

The current approach to healthcare investing is broken

We are on a mission to change that!

Traditional ways of investing do not work in healthcare. A collaborative approach that brings all stakeholders of a healthcare startup’s journey need to be at the table to make an informed and successful investment decision. HIP is shattering the status quo by bringing together financial (angel, family office, VC, PE) and strategic investors (payers, providers, delivery systems) into the analysis, due diligence, and advisory roles of our portfolio companies.

Managing Partner & Founder, HIP

HIP Advisory Board

Dr. rakesh patel

CHIEF MEDICAL OFFICER OF DIGITAL HEALTH, INVITAE AND CO-FOUNDER, HIP

kamal gogineni

Founder/CEO Medneon (acquired by Invitae)

Raz zia

CO-FOUNDER AND PARTNER, ALDRICH CAPITAL PARTNERS

keith winter

Partner, Teal Ventures

Testimonials

NAME

Title

Testimonial will go here

NAME

Title

Testimonial will go here

NAME

Title

Testimonial will go here

NAME

Title

Testimonial will go here

NAME

Title

Testimonial will go here

NAME

Title

Testimonial will go here

faq

What size check do you write in follow-on?

Answer will go here

Where are you located?

Answer will go here

Where do you geographically invest?

Answer will go here

How big is the fund?

Answer will go here

Who are your LPs?

Answer will go here

What is your relationship to BAHA?

Answer will go here

Who are your affiliate partners?

Answer will go here

How does a startup submit to be considered?

Answer will go here

Does HIP lead rounds?

Answer will go here

Do you take a board seat?

Answer will go here

Do you syndicate an investment?

Answer will go here

What is the min contribution to be considered and LP?

Answer will go here

Why an annual focused fund?

Answer will go here

Can I invest more if I like a deal?

Answer will go here

Disclaimer

The contents of this website are provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security of HIP Fund I or its affiliates in any jurisdiction. HIP Fund I does not intend to solicit and is not soliciting, any action with respect to any Security or any other contractual relationship. Nothing on this website or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or in any other jurisdiction in which such an offer or solicitation is unlawful. HIP Fund I does not make investment recommendations and no communication, through this website or in any other information materials, should be construed as a recommendation for any security. Nothing on this website is intended to constitute legal, tax, securities or investment advice, or opinion regarding the appropriateness of any investment.

This website has been provided to you with the expressed understanding that information contained herein, or made available in connection with any further investigation, is strictly confidential and is intended for your exclusive use. Your receipt of this information is your acknowledgment and agreement that this website and the information contained herein will be maintained in strict confidence and will not be disclosed by you to any third party without the expressed written consent of the Fund. This website and the information contained herein may be disclosed only to your employees, consultants and agents who need to know such information to evaluate an investment in the Fund. Neither this website nor any information contained herein shall be photocopied or reproduced at any time.

Statements on this website describing the Funds’ objectives, projections, estimates, expectations or predictions may be “forward-looking statements” within the meaning of the applicable securities laws and regulations. Such statements are based on beliefs, assumptions, data, and other information currently available to us. Actual results could differ materially from those expressed or implied on this website.

Any investment in the Fund is only intended for accredited investors and qualified investment entities. Investments in early-stage ventures are speculative in nature and involve a high degree of risk. Those investors who cannot afford to lose their entire investment should not invest in such projects. There is no guarantee that the stated project valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive restricted ownership that may be subject to holding period requirements. Early-stage investments should only be part of your overall private investment portfolio. Investors who cannot hold an investment for at least 5 years should not invest.

The information contained herein is subject to change without notice.